GSK decides to recall antacid Zinetac over safety concern
GSK Pharma said it has been contacted by regulatory authorities regarding detection of genotoxic nitrosamine NDMA in ranitidine products.
Also read:- GSK fights bid to strike new Zofran preemption evidence
Subsequently, Saraca Laboratories Ltd were notified by the European Directorate for V Quality of Medicines that its certificate of suitability for ranitidine hydrochloride has been suspended, it added.
GSK Pharma said it manufactures Ranitidine Hydrochloride IP Tablets in 150 mg and 300 mg (Zinetac) using API (Active Pharmaceutical Ingredient) from Saraca Laboratories Ltd and another supplier, SMS Lifesciences India Ltd, for supply to Indian market.
As a precautionary action, it has decided "to initiate a voluntary recall (pharmacy/retail level recall) of Zinetac Tablets 150 mg and 300 mg products manufactured in India using API sourced from Saraca Laboratories Ltd", the company said.
However, it said, the product manufactured using API from SMS Lifesciences India Limited will not be recalled at this point of time.
"However, all such products will remain on hold and they will not be released to the market while the company will await the test results," it added.
Also read:- GSK receives USFDA panel backing for OTC nicotine oral spray for smoking de-addiction
The company further said it is continuing with investigations into the potential source of the NDMA.
"These investigations include continued engagement with our API suppliers," the company said adding that Patient safety remains its utmost priority and the company is taking this issue very seriously.
Ranitidine hydrochloride is commonly used for treatment of ulcers of stomach and intestine.
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at email@example.com. Check out more about our bureau/team here